Diabetic microvascular complications: Can patients at risk be identified? A review

International Journal of Clinical Practice

Volumn 60, Issue 11, 2006, Pages 1471-1483

  Girach, Aniz ^a   Manner, D ^a   Porta, M ^b  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Diabetes; Microvascular complications; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT; PROTEIN KINASE C INHIBITOR;

AGE; AMPUTATION; BLINDNESS; BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; EARLY DIAGNOSIS; HEALTH CARE COST; HEREDITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIFE EXPECTANCY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ADOLESCENT; ADULT; AGE OF ONSET; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; PREVALENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33749821010     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01175.x     Document Type: Review

References (132)

1. National Service Framework for Diabetes: Standards. London, UK: Department of Health, 2001.
2. The World Health Organization website. http://www.who.int/mediacentre/ factsheets/fs236/en/ (last accessed July 2006).
3. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet Med 1997; 14 (Suppl. 5): S1-85.
4. Krishnamurti U, Steffes MW. Glycohemoglobin: A primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem 2001; 47: 1157-65.
5. Harris MI, Klein R, Welborn TA, Knutman MW. Onset of NIDDM occurs at least 4-7yr before clinical diagnosis. Diabetes Care 1992; 15: 815-9.
6. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. UK Prospective Study Group. Diabetologia 1991; 34: 877-90.
7. Statistics provided by UK Diabetes Information Audit and Benchmarking Service (UKDIABS). UK. 2000: Diabetes.
8. Morgan CL, Currie CJ, Stott NCH, Smithers M, Butler CC, Peters JR. The prevalence of multiple diabetes-related complications. Diabet Med 2000; 17: 146-51.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
10. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13.
11. Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002; 11: 1205-23.
12. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes 1997; 46: 1829-39.
13. Ratner RE. The Diabetes Prevention Program Research. An update on the Diabetes Prevention Program. Endocr Pract 2006; 12: 20-4.
14. Rajala U, Pajunpaa H, Koskela P, Keinanen-Kickaanniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care 2000; 23: 957-61.
15. Khaleeli AA, Fear S, Maitland H, Maloney A. Diabetic retinopathy. Outcome at five-year follow-up of 203 people with diabetes. 2: Analysis. Practical Diabetes Int 1999; 16: 68-70.
16. Henricsson M, Nilsson A, Heijl A, Janzon L, Groop I. Mortality in diabetic patients participating in an ophthalmological control and screening programme. Diabet Med 1997; 14: 576-83.
17. Harding S. Extracts from "Concise Clinical Evidence. Diabetic retinopathy. BMJ 2003; 326: 1023-5.
18. Cunha-Vaz J. Lowering the risk of visual impairment and blindness. Diabet Med 1998; 15 (Suppl. 4): S47-50.
19. Schmechel H, Heinrich U. Retinopathy and nephropathy in 772 insulin-treated diabetic patients in relation to the type of diabetes. Diabet Metab 1993; 19: 138-42.
20. Microvascular and acute complications in IDDM patients: The EURODIAB IDDM Complications Study. Diabetologia 1994; 37: 278-85.
21. Malone JI, Morrison AD, Pavan PR, Cuthbertson DD. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5years'duration screened for the Diabetes Control and Complications Trial. Diabetes Care 2001; 24: 522-6.
22. Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye 2002; 16: 140-5.
23. Squadrito G, Cucinotta D. The late complications of diabetes mellitus. Ann Ital Med Int 1991; 6: 126-36.
24. Kohner EM, Aldington SJ, Stratton IM et al. for the United Kingdom Prospective Diabetes Study. United Kingdom Prospective Diabetes Study, 30: Diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 1998; 116: 297-303.
25. Klein R, Klein BEK, Moss SE, Linton LP. The Beaver Dam Eye Study. Retinopathy in adults with newly discovered and previously diagnosed diabetes mellitus. Ophthalmology 1992; 99: 58-62.
26. Tapp RJ, Shaw JE, Harper CA et al. on behalf of the AusDiab Study Group. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care 2003; 26: 1731-7.
27. Broadbent DM, Scott JA, Vora JP, Harding SP. Prevalence of diabetic eye disease in an inner city population: The Liverpool Diabetic Eye Study. Eye 1999; 13: 160-5.
28. Khandekar R, Al Lawatii J, Mohammed AJ, Al Raisi A. Diabetic retinopathy in Oman: A hospital based study. Br J Ophthalmol 2003; 87: 1061-4.
29. Segato T, Midena E, Grigoletto F et al., Veneto Group for Diabetic Retinopathy. The epidemiology and prevalence of diabetic retinopathy in the Veneto region of north east Italy. Diabet Med 1991; 8: S11-6.
30. Lopez IM, Diez A, Velilla S, Rueda A, Alvarez A, Pastor JC. Prevalence of diabetic retinopathy and eye care in rural area of Spain. Ophthalmic Epidemiol 2002; 9: 205-14.
31. Orchard TJ, Dorman JS, Maser RE et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990; 39: 1116-24.
32. Klein R, Klein BEK, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: An update. Aust N Z J Ophthalmol 1990; 18: 19-22.
33. Wirta OR, Pasternack AI, Oksa HH et al. Occurrence of late specific complications in type II (non-insulin dependent) diabetes mellitus. J Diabetes Complications 1995; 9: 177-85.
34. Straub RH, Zietz B, Palitzsch KD, Scholmerich J. Impact of disease duration on cardiovascular and papillary autonomic nervous function in IDDM and NIDDM patients. Diabetes Care 1996; 19: 960-7.
35. Klein RK, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30years. Arch Ophthalmol 1984; 102: 520-6.
36. Henricsson M, Nilsson A, Janzon L, Groop L. The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14: 123-31.
37. Vogt L, Jutzi E, Michaelis D. Different frequencies of diabetic complications in insulin-treated patients with diabetes of comparable duration, in relation to age at onset of diabetes. Soz Praventivmed 1992; 37: 231-6.
38. Kostraba JN, Dorman JS, Orchard TJ et al. Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 1989; 12: 686-93.
39. Cahill M, Halley A, Codd M et al. Prevalence of diabetic retinopathy in patients with diabetes mellitus diagnosed after the age of 70years. Br J Ophthalmol 1997; 81: 218-22.
40. HirveläH, Laatikainen L. Diabetic retinopathy in people aged 70years or older. The Oulu Eye Study. Br J Ophthalmol 1997; 81: 214-7.
41. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III Prevalence and risk of diabetic retinopathy when age at diagnosis is 30years or more. Arch Ophthalmol 1984; 102: 527-32.
42. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR, for the UK Prospective Diabetes Study (UKPDS) Group. Microaneurysms in the development of diabetic retinopathy (UKPDS 42). Diabetologia 1999; 42: 1107-12.
43. Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001; 18: 178-84.
44. Chase HP, Jackson WE, Hoops SL, Cockerham RS, Archer PG, O'Brien D. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989; 261: 1155-60.
45. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995; 113: 36-51.
46. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-98.
47. Reichard P. Are there any glycemic thresholds for the serious microvascular diabetic complications? J Diabetes Complications 1995; 9: 25-30.
48. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996; 276: 1409-15.
49. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 1999; 22: 99-111.
50. The Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA 2002; 287: 2563-9.
51. White NH, Cleary PA, Tamborlane WV et al. Effect of prior intensive therapy (IT) in Type 1 Diabetes (T1D) on 10-year progression of retinopathy in DCCT/EDIC: Comparison of adults and adolescents. ADA Annual Meeting 2005; (Abstract 919P).
52. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
53. Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-303.
54. Nathan DM, Cleary PA, Backlund JC et al. Intensive diabetes treatment and cardiovascular disease in patients with Type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
55. The Diabetes Control and Complications Trial Research Group. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116: 874-86.
56. Maberley DAL, King W, Cruess AF, Koushik A. Risk factors for diabetic retinopathy in the Cree of James Bay. Ophthalmic Epidemiol 2002; 9: 153-67.
57. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-17.
58. Adler AI, Stratton IM, Nei HAW et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000; 321: 412-9.
59. Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 1995; 18: 785-92.
60. Stratton IM, Kohner EM, Aldington SJ et al. for the UKPDS Group, UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6years from diagnosis. Diabetologia 2001; 44: 156-63.
61. Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in Type 1 diabetes. Ophthalmology 1998; 105: 1801-15.
62. Chase HP, Garg SK, Marshall G et al. Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 1991; 265: 614-7.
63. Moss SE, Klein R, Klein BE. Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 1996; 103: 1438-42.
64. Chew EY, Klein ML, Ferris FL III et al. for the ETDRS Research Group. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114: 1079-84.
65. Fong DS, Ferris FL III, Davis MD, Chew EY, for the early treatment diabetic retinopathy study research group. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS Report No. 24. Am J Ophthalmol 1999; 127: 137-41.
66. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract 1998; 41: 131-7.
67. Chiarelli F, de Martino M, Mezzetti A et al. Advanced glycation end products in children and adolescents with diabetes: Relation to glycemic control and early microvascular complications. J Pediatr 1999; 134: 486-91.
68. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 1829-39.
69. Zhang LY, Krzentowski G, Albert A, Lefebrve PJ. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001; 24: 1275-9.
70. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
71. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, on behalf of the UKPDS Group. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.
72. Krolewski AS, Warram JH. Natural history of diabetic nephropathy: How much can it be changed? Diabetes Rev 1995; 3: 446-59.
73. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease: With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32 (Suppl. 2): 64-78.
74. Molitch ME, Rutledge B, Steffes M, Cleary P. Renal insufficiency in the absence of albuminuria among adults with Type 1 diabetes in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study. ADA Annual Meeting 2006 (Abstract 23-OR).
75. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989; 4: 859-63.
76. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-20.
77. Gerstein HC, Mann JF, Yi Q et al. for the HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
78. Waeber B, Feihl F, Ruilope L. Diabetes and hypertension. Blood Press 2001; 10: 311-21.
79. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. JAMA 1997; 278: 2069-74.
80. Klein R, Klein SE, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 1999; 22: 743-51.
81. Fogarty DG, Krolewski AS. Genetic susceptibility and the role of hypertension in diabetic nephropathy. Curr Opin Nephrol Hypertens 1997; 6: 184-91.
82. Borch-Johnsen K, Norgaard K, Hommel E. Is diabetic nephropathy an inherited complication? Kidney Int 1992; 41: 719-22.
83. Bakman M, Yuskel B, Topaloglu AK, Mungan NO, Özler G. Risk factors for microalbuminuria in children and adolescents with insulin dependent diabetes mellitus. Ann Med Sci 2001; 10: 156-9.
84. Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-5.
85. The Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of Type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003; 290: 2159-67.
86. United Kingdom Prospective Diabetes Study Group, UK Prospective Diabetes Study (UKPDS). X. Urinary albumin excretion over 3years in diet-treated Type 2 (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36: 1021-9.
87. Sawicki PT, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17: 126-31.
88. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: A 10-year prospective observational study. Diabetes Care 2002; 25: 859-64.
89. Gambaro G, Bax G, Fusaro M et al. Cigarette smoking is a risk factor for nephropathy and its progression in Type 2 diabetes mellitus. Diabetes Nutr Metab 2001; 14: 337-42.
90. Ikeda Y, Suehiro T, Takamatsu K, Yamashita H, Tamura T, Hashimoto K. Effect of smoking on the prevalence of albuminuria in Japanese men with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1997; 36: 57-61.
91. Makino H, Shikata K, Kushiro M et al. Roles of advanced glycation end-products in the progression of diabetic nephropathy. Nephrol Dial Transplant 1996; 11 (Suppl. 5): 76-80.
92. Sugiyama S, Miyata T, Horie K et al. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 1996; 11: 91-4.
93. Tarnow L, Rossing P, Nielsen FS, Fagerudd JA, Poirier O, Parving HH. Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000; 23: 30-3.
94. Mitchell BD, Hawthorne VM, Vinik AI. Cigarette smoking and neuropathy in diabetic patients. Diabetes Care 1990; 13: 434-7.
95. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-8.
96. Yang Q, Kaji R, Takagi T et al. Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy. Brain 2001; 124: 1149-55.
97. Dickinson PJ, Carrington AL, Frost GS, Boulton AJM. Neurovascular disease, antioxidants and glycation in diabetes. Diabetes Metab Res Rev 2002; 18: 260-72.
98. Forsblom CM, Sane T, Groop PH et al. Risk factors for mortality in Type II (non-insulin-dependent) diabetes: Evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologica 1998; 41: 1253-62.
99. Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60: 2445-64.
100. Vincent AM, Feldman EL. New insights into the mechanisms of diabetic neuropathy. Rev Endocr Metab Disord 2004; 5: 227-36.
101. Malik RA, Newrick PG, Sharma AK et al. Microangiopathy in human diabetic neuropathy: Relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 1989; 32: 92-102.
102. O'Hare JA, Abuaisha F, Geoghegan M. Prevalence and forms of neuropathic morbidity in 800 diabetics. Ir J Med Sci 1994; 163: 132-5.
103. Tentolouris N, Pagoni S, Tzonou A, Katsilambros N. Peripheral neuropathy does not invariably co-exist with autonomic neuropathy in diabetes mellitus. Eur J Intern Med 2001; 12: 20-7.
104. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: Scope of the syndrome. Am J Med 1999; 107: 2S-8S.
105. Levitt NS, Stansberry KB, Wynchank S, Vinik AI. The natural progression of autonomic neuropathy and autonomic function tests in a cohort of people with IDDM. Diabetes Care 1996; 19: 751-4.
106. Cohen JA, Jeffers BW, Faldut D, Maroux M, Schrier RW. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin dependent diabetes mellitus (NIDDM). Muscle Nerve 1998; 21: 72-80.
107. Shalitin S, Josefsberg Z, Lilos P, De-Vries L, Phillip M, Weintrob N. Bedside scoring procedure for the diagnosis of diabetic peripheral neuropathy in young patients with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15: 613-20.
108. Litchy W, Dyck P, Tesfaye S, Zhang D, Bastyr E, the MBBQ Study Group. Diabetic peripheral neuropathy (DPN) assessed by neurological examination (NE) and composite scores (CS) is improved with LY333531 treatment. Diabetes 2002; 51: A197-8.
109. Coppini DV, Weng C, Young PJ, Sönksen PH. The 'VPTscore'-a useful predictor of neuropathy in diabetic patients. Diabet Med 2000; 17: 488-90 (Letter).
110. Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sönksen PH. The natural history of diabetic peripheral neuropathy determined by a 12year prospective study using vibration perception thresholds. J Clin Neurosci 2001; 8: 520-4.
111. Barbosa AP, Medina JL, Ramos EP, Barros HP, and the DPN in Porto Study Group. Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population. Diabetes Metab 2001; 27: 496-502.
112. Tesfaye S, Stevens LK, Stephenson JM et al. and the EURODIAB IDDM Study Group. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377-84.
113. Fedele D, Comi G, Coscelli C et al. A multicentre study on the prevalence of diabetic neuropathy in Italy. Diabetes Care 1997; 20: 836-43.
114. Maser RE, Steenkiste AR, Dorman JS et al. Epidemiological correlates of diabetic neuropathy. Report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989; 38: 1456-61.
115. The Diabetes Control and Complications Trial Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). Diabetes 1988; 37: 476-81.
116. Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Smith DG. Risk factors for diabetic peripheral sensory neuropathy: Results of the Seattle Prospective Diabetic Foot Study. Diabetes Care 1997; 20: 1162-7.
117. Dyck PJ, Davies JL, Wilson DM, Service EJ, Melton LJ, O'Brien PC. Risk factors for severity of diabetic polyneuropathy: Intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22: 1479-86.
118. Swade TF, Emanuele NV. Alcohol and diabetes. Compr Ther 1997; 23: 135-40.
119. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995; 38: 869-80.
120. Martin CL, Albers J, Herman WH et al. Neuropathy among diabetes control and complications trial cohort 8years after trial completion. Diabetes Care 2006; 29: 340-4.
121. Toyry JP, Niskanen LK, Mantysaari MJ, Lansimies EA, Uusitupa MIJ. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM: Ten year follow-up from the diagnosis. Diabetes 1996; 45: 308-15.
122. Partanen J, Niskanen L, Lehtinen J, Mervaala E, Siitonen O, Uusitopa M. Natural history of peripheral neuropathy in patients with non insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 89-94.
123. Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997; 20: 322-9.
124. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on healthcare costs: Results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). Diabet Med 2003; 20: 442-50.
125. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000; 14: 18-24.
126. United Kingdom Prospective Diabetes Study Group. Quality of life in Type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 1999; 22: 1125-36.
127. Genuth S, Sun W, Cleary P et al. Glycation and carboxymethyllsine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with Type 1 diabetes. Diabetes 2005; 54: 3103-11.
128. LeRoith D, Fonseca V, Vinik A. Metabolic memory in diabetes - focus on insulin. Diabetes Metab Res Rev 2005; 21: 85-90.
129. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002; 61: 1086-97.
130. Gray A, Clarke P, Farmer A, Holman R. on behalf of the United Kingdom Prospective Diabetes Study (UKPDS) Group. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: Cost analysis (UKPDS 63). BMJ 2002; 325: 860.
131. Molitch ME, Steffes MW, Cleary PA, Nathan DM. Baseline analysis of renal function in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Kidney Int 1993; 43: 668-74.
132. Stephenson JM, Fuller JH, Viberti GC, Sjolie AK, Navalesi R, the EURODIAB IDDM Complications Study Group. Blood pressure, retinopathy and urinary albumin excretion in IDDM: The EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 599-603.